Description: Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.
Home Page: www.theratech.com
TH Technical Analysis
2015 Peel Street
Montreal,
QC
H3A 1T8
Canada
Phone:
514 336 7800
Officers
| Name | Title |
|---|---|
| Mr. Paul Lévesque | Pres, CEO & Director |
| Mr. Philippe Dubuc M.B.A., MBA | Sr. VP & CFO |
| Dr. Christian Marsolais Ph.D. | Sr. VP & Chief Medical Officer |
| Mr. John Leasure | Global Commercial Officer |
| Ms. Elif McDonald | Sr. Director of Investor Relations |
| Mr. Jocelyn Lafond L.L.M., LL.B. | Gen. Counsel & Corp. Sec. |
| Mr. Denis Boucher B.A., L.L.B. | VP of Communications & Corp. Affairs |
| Hon. Andre Dupras M.Sc. | VP of HR |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 55.2486 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 19.4616 |
| Price-to-Sales TTM: | 1.5982 |
| IPO Date: | |
| Fiscal Year End: | November |
| Full Time Employees: | 87 |